Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
2020 · Scientific Reports · 41 citations
https://doi.org/10.1038/s41598-020-67385-9
F
Fei Kang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
160
Papers
2.6K
Citations
28
h-index
55
i10-index
Fei Kang is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Prostate Cancer Diagnosis and Treatment & Peptidase Inhibition and Analysis. The author has an h-index of 28, co-authored 136 publications.
ORCID: 0000-0003-0267-7819Papers by this author
worksEvaluation of the stability of cucurbit[8]uril-based ternary host−guest complexation in physiological environment and the fabrication of a supramolecular theranostic nanomedicine
2021 · Journal of Nanobiotechnology · 28 citations
https://doi.org/10.1186/s12951-021-01076-z
Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China
2024 · Journal of Nuclear Medicine · 26 citations
https://doi.org/10.2967/jnumed.123.266983
Unsymmetrical cyanine dye via in vivo hitchhiking endogenous albumin affords high-performance NIR-II/photoacoustic imaging and photothermal therapy
2021 · Journal of Nanobiotechnology · 25 citations
https://doi.org/10.1186/s12951-021-01075-0
First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody
2024 · European Journal of Nuclear Medicine and Molecular Imaging · 23 citations
https://doi.org/10.1007/s00259-023-06584-8
Landscape of Nuclear Medicine in China and Its Progress on Theranostics
2024 · Journal of Nuclear Medicine · 22 citations
https://doi.org/10.2967/jnumed.123.266968
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat